Xu · Biomolecules 2024 · narrative review · n=?

VDAC in Retinal Health and Disease.

Cited 9 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Narrative review of preclinical and mechanistic studies without original clinical data.

PubMed 38927058 · doi:10.3390/biom14060654 · record verified 2026-08-27

What was done

This narrative review summarizes published literature on the localization, physiological roles, and pathogenic mechanisms of voltage-dependent anion channel (VDAC) isoforms (VDAC1, VDAC2, VDAC3) in retinal health and degenerative diseases.

What was found

The abstract reports no quantitative data or specific statistical metrics. Mechanistically, all three VDAC isoforms are expressed in the retina, with VDAC2 and VDAC3 prominently expressed in most retinal cells, and VDAC2 co-expressed with HK2 and PKM2 in photoreceptors. VDAC overexpression is observed in retinitis pigmentosa, age-related macular degeneration, and glaucoma models, where antioxidant treatment or inhibition of VDAC oligomerization reduced VDAC expression and enhanced cell survival.

Why it matters

It highlights VDAC as a mitochondrial regulator of retinal metabolism and apoptosis, identifying VDAC oligomerization inhibition as a candidate therapeutic approach for retinal degenerations.

Limits

This is a narrative review with no original empirical data or systematic search methodology reported. The exact localization and distinct functional roles of individual VDAC isoforms in specific retinal cell types remain undefined, and therapeutic findings derive from preclinical models without clinical trial validation.

Cited by